05 Aug 2026
2 months ago
595 views
Associate Health Minister David Seymour welcomes Pharmac’s decision to expand access to type 2 diabetes medicines based on clinical need, benefiting over 30,000 patients regardless of ethnicity. From 1 September, medicines like empagliflozin and liraglutide will be funded for anyone with high blood sugar despite other treatments, removing previous restrictions related to cardiovascular or renal conditions. This change, supported by community feedback and a new supplier agreement, aims to improve health outcomes, reduce complications, and optimize health budget efficiency.
14 May 2026
5 months ago
968 views
Associate Health Minister David Seymour and Health Minister Simeon Brown support Pharmac’s proposal to expand funding for three type 2 diabetes medicines by removing ethnicity-based criteria and lowering cardiovascular risk thresholds, aiming to improve access based on clinical need. If approved, the changes could benefit up to 23,000 more people over five years, enhancing early treatment to reduce complications and hospital admissions. This initiative aligns with the Government’s broader commitment to equitable, needs-based healthcare and increased health system funding to improve outcomes for all New Zealanders.
01 Feb 2026
8 months ago
1243 views
New Zealand now allows prescriptions for up to 12 months for patients with stable, long-term conditions, reducing costs and simplifying medicine access by eliminating the need for quarterly GP visits. This change lowers prescription charges to a single $5 fee at the first collection and frees up GP time for other patients. Additionally, expanded prescribing rights for health professionals like nurse practitioners further improve timely and affordable healthcare access.